Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis [1]

Leukemia

Volumn 20, Issue 2, 2006, Pages 350-353

  James, C ^a,b   Delhommeau, F ^a,b   Marzac, C ^a   Teyssandier, I ^a   Le Couedic J P ^b   Giraudier, S ^b,c   Roy, L ^b,d   Saulnier, P ^e   Lacroix, L ^e   Maury, S ^c   Tulliez, M ^c   Vainchenker, W ^b   Ugo, Valerie ^a,f,g   Casadevall, N ^a,b,g  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c Service d'Hématologie   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; JANUS KINASE 2;

ADULT; AGED; CELL LINE; CORRELATION ANALYSIS; CYTOGENETICS; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; ERYTHROCYTOSIS; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; GENOTYPE; HEMATOCRIT; HUMAN; IDIOPATHIC DISEASE; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SPLENOMEGALY;

EID: 31444439623     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404069     Document Type: Letter

References (8)

1. Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma 1996; 22 (Suppl 1): 87-93.
2. Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Polycythaemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours; Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 32-34.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in Polycythemia Vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
7. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Huntly BJ et al. A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. Hematology (Am Soc Hematol Educ Prog) 2000, 51-68.
8. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.